Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Growth-inhibition of cell lines derived from B cell lymphomas through antagonism of serotonin receptor signaling.

Kolan SS, Lidström T, Mediavilla T, Dernstedt A, Degerman S, Hultdin M, Björk K, Marcellino D, Forsell MNE.

Sci Rep. 2019 Mar 12;9(1):4276. doi: 10.1038/s41598-019-40825-x.

2.

Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.

Luis-Ravelo D, Estévez-Silva H, Barroso-Chinea P, Afonso-Oramas D, Salas-Hernández J, Rodríguez-Núñez J, Acevedo-Arozena A, Marcellino D, González-Hernández T.

Exp Neurol. 2018 Jan;299(Pt A):137-147. doi: 10.1016/j.expneurol.2017.10.019. Epub 2017 Oct 19.

PMID:
29056363
3.

An altered blood-brain barrier contributes to brain iron accumulation and neuroinflammation in the 6-OHDA rat model of Parkinson's disease.

Olmedo-Díaz S, Estévez-Silva H, Orädd G, Af Bjerkén S, Marcellino D, Virel A.

Neuroscience. 2017 Oct 24;362:141-151. doi: 10.1016/j.neuroscience.2017.08.023. Epub 2017 Aug 24.

PMID:
28842186
4.

Rho-kinase inhibitor Y-27632 and hypoxia synergistically enhance chondrocytic phenotype and modify S100 protein profiles in human chondrosarcoma cells.

Piltti J, Bygdell J, Fernández-Echevarría C, Marcellino D, Lammi MJ.

Sci Rep. 2017 Jun 16;7(1):3708. doi: 10.1038/s41598-017-03958-5.

5.

Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.

Sahlholm K, Sijbesma JW, Maas B, Kwizera C, Marcellino D, Ramakrishnan NK, Dierckx RA, Elsinga PH, van Waarde A.

Psychopharmacology (Berl). 2015 Sep;232(18):3443-53. doi: 10.1007/s00213-015-3997-8. Epub 2015 Jul 11.

6.

Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.

Gellhaar S, Marcellino D, Abrams MB, Galter D.

Genes Brain Behav. 2015 Mar;14(3):260-70. doi: 10.1111/gbb.12210. Erratum in: Genes Brain Behav. 2015 Jun;14(5):442.

7.

Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor.

Sahlholm K, Marcellino D, Nilsson J, Ögren SO, Fuxe K, Århem P.

Int J Neuropsychopharmacol. 2014 Jan;17(1):149-55. doi: 10.1017/S1461145713000801. Epub 2013 Sep 30.

PMID:
24074141
8.

Intercalated and paracapsular cell islands of the adult rat amygdala: a combined rapid-Golgi, ultrastructural, and immunohistochemical account.

Marcellino D, Frankowska M, Agnati L, Perez de la Mora M, Vargas-Barroso V, Fuxe K, Larriva-Sahd J.

Neuroscience. 2012 Dec 13;226:324-47. doi: 10.1016/j.neuroscience.2012.08.067. Epub 2012 Sep 15.

PMID:
22986165
9.

Voltage sensitivities and deactivation kinetics of histamine H₃ and H₄ receptors.

Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P.

Biochim Biophys Acta. 2012 Dec;1818(12):3081-9. doi: 10.1016/j.bbamem.2012.07.027. Epub 2012 Aug 2.

10.

Effects of cocaine self-administration and extinction on D2 -like and A2A receptor recognition and D2 -like/Gi protein coupling in rat striatum.

Frankowska M, Marcellino D, Adamczyk P, Filip M, Fuxe K.

Addict Biol. 2013 May;18(3):455-66. doi: 10.1111/j.1369-1600.2012.00452.x. Epub 2012 Apr 13.

PMID:
22500978
11.

A novel mechanism of cocaine to enhance dopamine d2-like receptor mediated neurochemical and behavioral effects. An in vivo and in vitro study.

Ferraro L, Frankowska M, Marcellino D, Zaniewska M, Beggiato S, Filip M, Tomasini MC, Antonelli T, Tanganelli S, Fuxe K.

Neuropsychopharmacology. 2012 Jul;37(8):1856-66. doi: 10.1038/npp.2012.33. Epub 2012 Mar 28.

12.

The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the σ-1 receptor.

Sahlholm K, Århem P, Fuxe K, Marcellino D.

Mol Psychiatry. 2013 Jan;18(1):12-4. doi: 10.1038/mp.2012.3. Epub 2012 Feb 21. No abstract available.

PMID:
22349783
13.

GPCR heteromers and their allosteric receptor-receptor interactions.

Fuxe K, Borroto-Escuela DO, Marcellino D, Romero-Fernandez W, Frankowska M, Guidolin D, Filip M, Ferraro L, Woods AS, Tarakanov A, Ciruela F, Agnati LF, Tanganelli S.

Curr Med Chem. 2012;19(3):356-63. Review.

PMID:
22335512
14.

Distribution of dopamine D(2)-like receptors in the rat amygdala and their role in the modulation of unconditioned fear and anxiety.

Perez de la Mora M, Gallegos-Cari A, Crespo-Ramirez M, Marcellino D, Hansson AC, Fuxe K.

Neuroscience. 2012 Jan 10;201:252-66. doi: 10.1016/j.neuroscience.2011.10.045. Epub 2011 Nov 11.

PMID:
22100273
15.

Increased affinity of dopamine for D(2) -like versus D(1) -like receptors. Relevance for volume transmission in interpreting PET findings.

Marcellino D, Kehr J, Agnati LF, Fuxe K.

Synapse. 2012 Mar;66(3):196-203. doi: 10.1002/syn.21501. Epub 2011 Nov 18.

PMID:
22034017
16.

Agonist-specific voltage sensitivity at the dopamine D2S receptor--molecular determinants and relevance to therapeutic ligands.

Sahlholm K, Barchad-Avitzur O, Marcellino D, Gómez-Soler M, Fuxe K, Ciruela F, Arhem P.

Neuropharmacology. 2011 Oct-Nov;61(5-6):937-49. doi: 10.1016/j.neuropharm.2011.06.022. Epub 2011 Jul 5.

PMID:
21752340
17.

Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices.

Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, Gómez-Soler M, Corrales F, Marcellino D, Narvaez M, Frankowska M, Flajolet M, Heintz N, Agnati LF, Ciruela F, Fuxe K.

Biochem Biophys Res Commun. 2010 Nov 26;402(4):801-7. doi: 10.1016/j.bbrc.2010.10.122. Epub 2010 Oct 30.

PMID:
21040702
18.

Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine.

Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, Mallol J, Cortés A, Casadó V, Canela EI, Ortiz J, Fuxe K, Lluís C, Ferré S, Franco R.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18676-81. doi: 10.1073/pnas.1008911107. Epub 2010 Oct 18.

19.

Dopamine D2 and 5-hydroxytryptamine 5-HT(₂A) receptors assemble into functionally interacting heteromers.

Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, Marcellino D, Ciruela F, Agnati LF, Fuxe K.

Biochem Biophys Res Commun. 2010 Oct 29;401(4):605-10. doi: 10.1016/j.bbrc.2010.09.110. Epub 2010 Oct 1.

PMID:
20888323
20.

The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions.

Fuxe K, Marcellino D, Borroto-Escuela DO, Frankowska M, Ferraro L, Guidolin D, Ciruela F, Agnati LF.

J Recept Signal Transduct Res. 2010 Oct;30(5):272-83. doi: 10.3109/10799893.2010.506191. Review.

PMID:
20684666
21.

Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice.

Marcellino D, Lindqvist E, Schneider M, Müller CE, Fuxe K, Olson L, Galter D.

Neurobiol Dis. 2010 Nov;40(2):460-6. doi: 10.1016/j.nbd.2010.07.008. Epub 2010 Jul 23.

PMID:
20656029
22.

On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.

Marcellino D, Suárez-Boomgaard D, Sánchez-Reina MD, Aguirre JA, Yoshitake T, Yoshitake S, Hagman B, Kehr J, Agnati LF, Fuxe K, Rivera A.

J Neural Transm (Vienna). 2010 Jun;117(6):681-7. doi: 10.1007/s00702-010-0400-0. Epub 2010 Apr 13.

PMID:
20387084
23.

Nanomolar concentrations of cocaine enhance D2-like agonist-induced inhibition of the K+-evoked [3H]-dopamine efflux from rat striatal synaptosomes: a novel action of cocaine.

Ferraro L, Beggiato S, Marcellino D, Frankowska M, Filip M, Agnati LF, Antonelli T, Tomasini MC, Tanganelli S, Fuxe K.

J Neural Transm (Vienna). 2010 May;117(5):593-7. doi: 10.1007/s00702-010-0389-4. Epub 2010 Mar 31.

PMID:
20354886
24.

Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Fuxe K, Marcellino D, Borroto-Escuela DO, Guescini M, Fernández-Dueñas V, Tanganelli S, Rivera A, Ciruela F, Agnati LF.

CNS Neurosci Ther. 2010 Jun;16(3):e18-42. doi: 10.1111/j.1755-5949.2009.00126.x. Epub 2010 Mar 16. Review.

25.

Cocaine produces D2R-mediated conformational changes in the adenosine A(2A)R-dopamine D2R heteromer.

Marcellino D, Navarro G, Sahlholm K, Nilsson J, Agnati LF, Canela EI, Lluís C, Århem P, Franco R, Fuxe K.

Biochem Biophys Res Commun. 2010 Apr 16;394(4):988-92. doi: 10.1016/j.bbrc.2010.03.104. Epub 2010 Mar 20.

PMID:
20307491
26.

A serine point mutation in the adenosine A2AR C-terminal tail reduces receptor heteromerization and allosteric modulation of the dopamine D2R.

Borroto-Escuela DO, Marcellino D, Narvaez M, Flajolet M, Heintz N, Agnati L, Ciruela F, Fuxe K.

Biochem Biophys Res Commun. 2010 Mar 26;394(1):222-7. doi: 10.1016/j.bbrc.2010.02.168. Epub 2010 Mar 1.

PMID:
20197060
27.

Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization.

Borroto-Escuela DO, Narvaez M, Marcellino D, Parrado C, Narvaez JA, Tarakanov AO, Agnati LF, Díaz-Cabiale Z, Fuxe K.

Biochem Biophys Res Commun. 2010 Mar 19;393(4):767-72. doi: 10.1016/j.bbrc.2010.02.078. Epub 2010 Feb 18.

PMID:
20171159
28.

Differential sensitivity of A2A and especially D2 receptor trafficking to cocaine compared with lipid rafts in cotransfected CHO cell lines. Novel actions of cocaine independent of the DA transporter.

Genedani S, Carone C, Guidolin D, Filaferro M, Marcellino D, Fuxe K, Agnati LF.

J Mol Neurosci. 2010 Jul;41(3):347-57. doi: 10.1007/s12031-010-9328-y. Epub 2010 Feb 9.

PMID:
20143275
29.

Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis.

Fuxe K, Marcellino D, Leo G, Agnati LF.

Curr Opin Pharmacol. 2010 Feb;10(1):14-22. doi: 10.1016/j.coph.2009.10.010. Epub 2009 Nov 26. Review.

PMID:
19942481
30.

The discovery of central monoamine neurons gave volume transmission to the wired brain.

Fuxe K, Dahlström AB, Jonsson G, Marcellino D, Guescini M, Dam M, Manger P, Agnati L.

Prog Neurobiol. 2010 Feb 9;90(2):82-100. doi: 10.1016/j.pneurobio.2009.10.012. Epub 2009 Oct 21. Review.

PMID:
19853007
31.

Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis.

de la Mora MP, Gallegos-Cari A, Arizmendi-García Y, Marcellino D, Fuxe K.

Prog Neurobiol. 2010 Feb 9;90(2):198-216. doi: 10.1016/j.pneurobio.2009.10.010. Epub 2009 Oct 21. Review.

PMID:
19853006
32.

Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors.

Navarro G, Aymerich MS, Marcellino D, Cortés A, Casadó V, Mallol J, Canela EI, Agnati L, Woods AS, Fuxe K, Lluís C, Lanciego JL, Ferré S, Franco R.

J Biol Chem. 2009 Oct 9;284(41):28058-68. doi: 10.1074/jbc.M109.034231. Epub 2009 Jul 24.

33.

Brain receptor mosaics and their intramembrane receptor-receptor interactions: molecular integration in transmission and novel targets for drug development.

Fuxe K, Marcellino D, Guidolin D, Woods AS, Agnati L.

J Acupunct Meridian Stud. 2009 Mar;2(1):1-25. doi: 10.1016/S2005-2901(09)60011-X. Epub 2009 Apr 7. Review.

34.

Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia.

Fuxe K, Marcellino D, Woods AS, Giuseppina L, Antonelli T, Ferraro L, Tanganelli S, Agnati LF.

J Neural Transm (Vienna). 2009 Aug;116(8):923-39. doi: 10.1007/s00702-008-0174-9. Epub 2009 Jan 21. Review.

35.

Heterodimers and receptor mosaics of different types of G-protein-coupled receptors.

Fuxe K, Marcellino D, Guidolin D, Woods AS, Agnati LF.

Physiology (Bethesda). 2008 Dec;23:322-32. doi: 10.1152/physiol.00028.2008. Review.

36.

Voltage-sensitivity at the human dopamine D2S receptor is agonist-specific.

Sahlholm K, Marcellino D, Nilsson J, Fuxe K, Arhem P.

Biochem Biophys Res Commun. 2008 Dec 26;377(4):1216-21. doi: 10.1016/j.bbrc.2008.10.117. Epub 2008 Nov 5.

PMID:
18983826
37.

Differential voltage-sensitivity of D2-like dopamine receptors.

Sahlholm K, Marcellino D, Nilsson J, Fuxe K, Arhem P.

Biochem Biophys Res Commun. 2008 Sep 26;374(3):496-501. doi: 10.1016/j.bbrc.2008.07.052. Epub 2008 Jul 22.

PMID:
18652803
38.

Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum.

Marcellino D, Ferré S, Casadó V, Cortés A, Le Foll B, Mazzola C, Drago F, Saur O, Stark H, Soriano A, Barnes C, Goldberg SR, Lluis C, Fuxe K, Franco R.

J Biol Chem. 2008 Sep 19;283(38):26016-25. doi: 10.1074/jbc.M710349200. Epub 2008 Jul 21.

39.

How calmodulin interacts with the adenosine A(2A) and the dopamine D(2) receptors.

Woods AS, Marcellino D, Jackson SN, Franco R, Ferré S, Agnati LF, Fuxe K.

J Proteome Res. 2008 Aug;7(8):3428-34. doi: 10.1021/pr8001782. Epub 2008 Jul 1.

40.

Electrophysiology-based analysis of human histamine H(4) receptor pharmacology using GIRK channel coupling in Xenopus oocytes.

Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P.

Eur J Pharmacol. 2008 Sep 4;591(1-3):52-8. doi: 10.1016/j.ejphar.2008.06.029. Epub 2008 Jun 12.

PMID:
18582456
41.

On the key role played by altered protein conformation in Parkinson's disease.

Agnati LF, Baldelli E, Andreoli N, Woods AS, Vellani V, Marcellino D, Guidolin D, Fuxe K.

J Neural Transm (Vienna). 2008 Sep;115(9):1285-99. doi: 10.1007/s00702-008-0072-1. Epub 2008 Jun 5. Review.

PMID:
18528629
42.

Voltage-dependence of the human dopamine D2 receptor.

Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P.

Synapse. 2008 Jun;62(6):476-80. doi: 10.1002/syn.20509.

PMID:
18361445
43.

Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis.

Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Müller CE, Fisone G, Lluis C, Agnati LF, Franco R, Fuxe K.

Neuropharmacology. 2008 Apr;54(5):815-23. doi: 10.1016/j.neuropharm.2007.12.011. Epub 2008 Jan 9.

PMID:
18262573
44.

Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology.

Fuxe K, Marcellino D, Rivera A, Diaz-Cabiale Z, Filip M, Gago B, Roberts DC, Langel U, Genedani S, Ferraro L, de la Calle A, Narvaez J, Tanganelli S, Woods A, Agnati LF.

Brain Res Rev. 2008 Aug;58(2):415-52. doi: 10.1016/j.brainresrev.2007.11.007. Epub 2008 Jan 28. Review.

PMID:
18222544
45.

Structural plasticity in G-protein coupled receptors as demonstrated by the allosteric actions of homocysteine and computer-assisted analysis of disordered domains.

Agnati LF, Leo G, Genedani S, Andreoli N, Marcellino D, Woods A, Piron L, Guidolin D, Fuxe K.

Brain Res Rev. 2008 Aug;58(2):459-74. Epub 2007 Oct 22. Review.

PMID:
18022243
46.

Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol.

Borgkvist A, Marcellino D, Fuxe K, Greengard P, Fisone G.

Neuropharmacology. 2008 Jan;54(1):31-5. Epub 2007 Jul 6.

PMID:
17686497
47.

Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease.

Fuxe K, Marcellino D, Genedani S, Agnati L.

Mov Disord. 2007 Oct 31;22(14):1990-2017. Review.

PMID:
17618524
48.

The human histamine H3 receptor couples to GIRK channels in Xenopus oocytes.

Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P.

Eur J Pharmacol. 2007 Jul 19;567(3):206-10. Epub 2007 Apr 30.

PMID:
17537431
49.

From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission.

Fuxe K, Dahlström A, Höistad M, Marcellino D, Jansson A, Rivera A, Diaz-Cabiale Z, Jacobsen K, Tinner-Staines B, Hagman B, Leo G, Staines W, Guidolin D, Kehr J, Genedani S, Belluardo N, Agnati LF.

Brain Res Rev. 2007 Aug;55(1):17-54. Epub 2007 Mar 13. Review.

PMID:
17433836
50.

Increase in A2A receptors in the nucleus accumbens after extended cocaine self-administration and its disappearance after cocaine withdrawal.

Marcellino D, Roberts DC, Navarro G, Filip M, Agnati L, Lluís C, Franco R, Fuxe K.

Brain Res. 2007 Apr 27;1143:208-20. Epub 2007 Jan 28.

PMID:
17320828

Supplemental Content

Loading ...
Support Center